{"id":246206,"date":"2012-10-04T03:13:35","date_gmt":"2012-10-04T03:13:35","guid":{"rendered":"http:\/\/www.eugenesis.com\/stratadx-appoints-chief-financial-officer-executive-vice-president-of-sales-and-marketing-new-board-member\/"},"modified":"2012-10-04T03:13:35","modified_gmt":"2012-10-04T03:13:35","slug":"stratadx-appoints-chief-financial-officer-executive-vice-president-of-sales-and-marketing-new-board-member","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/stratadx-appoints-chief-financial-officer-executive-vice-president-of-sales-and-marketing-new-board-member.php","title":{"rendered":"StrataDx appoints Chief Financial Officer, Executive Vice President of Sales and Marketing, New Board Member"},"content":{"rendered":"<p><p>    LEXINGTON, Mass., Oct.3, 2012 \/PRNewswire\/    --StrataDx, a leader in anatomic pathology services,    announced today the appointments of Jim Agnello as Chief    Financial Officer, Greg Richard as Executive Vice President of    Sales & Marketing, and Steve Casper to its Board of    Directors.StrataDx provides clinicians with    high-quality pathology services in the fields of dermatology,    urology, podiatry, oral pathology, gastroenterology and    gynecology.  <\/p>\n<p>    Jim Agnello, CPA, joins StrataDx as the Chief Financial Officer    and brings over two decades of financial & laboratory    operational expertise. Mr. Agnello served as the    Chief Financial Officer of Clarient and Nodality and most    recently, as the Vice President of Operations for    Healthtronics, Inc. He also spent 18 years with    SmithKline Beecham in a variety of senior financial    positions. Jim has a a Master's Degree in    Accounting from the Wharton School at the University of    Pennsylvania and a Bachelors Degree in Business Administration    from Rutgers, the State University of New Jersey.  <\/p>\n<p>    Greg Richard joins the company as the Executive Vice President    of Sales & Marketing and brings extensive senior sales    leadership expertise in not only the laboratory industry, but    in Managed Care, Biotech, and Clinical Trials as well.    Most recently, he was the Chief Commercial Officer at Signal    Genetics, a specialty molecular testing Company, and served    previously as the Sales Officer for LabCorp's Northeast    Division and the Vice President of Managed Care and Global    Sales and Marketing for Clinical Trials at Quest    Diagnostics. Greg received a B.A. from Westminster    College.  <\/p>\n<p>    Steven E. Casper has been named to the board of    StrataDx. He is currently the Chief Executive    Officer of National Dentex Corporation. Mr. Casper has    significant experience developing successful health care    organizations. Prior to National Dentex, Mr. Casper was    involved the founding and development of AmeriPath and Dermpath    Diagnostics, both leading providers of pathology    services. Mr. Casper served as the President of Dermpath    Diagnostics, a division of Quest Diagnostics, Inc. and    previously held senior executive roles at AmeriPath and Summit    Partners. Steven received a B.A from Boston College.  <\/p>\n<p>    \"These appointments represent a significant milestone for    StrataDx. Greg and Jim both have stellar track    records of driving growth and generating value in their    respective organizations,\" said Pat Noland, Chief Executive    Officer, StrataDx.  <\/p>\n<p>    Richard Novak, Chairman of the StrataDx Board of Directors    adds, \"We are pleased to welcome Steven to the    Board. His breadth of knowledge and expertise will    contribute to the ongoing evolution of StrataDx as a best in    class pathology services organization.\"  <\/p>\n<p>    About StrataDx  <\/p>\n<p>    (www.strataDx.com)  <\/p>\n<p>    StrataDx is a full service anatomic pathology laboratory that    offers services in all areas of surgical pathology and cytology    as well as molecular diagnostics and immunoflorescence.    The pathology team is comprised of members with subspecialty    board certification in dermatopathology, hematopathogy,    cytopathology, nuclear medicine, clinical pathology, and the    majority of the pathologists have more than two decades of    medical experience. Many also have teaching appointments    at some of the nation's most prestigious academic medical    centers including Harvard, Tufts, and the Univ. of    Pennsylvania. StrataDx services customers ranging from    major regional hospitals to small, independent physician    practices in more than 40 states. Headquartered in Lexington,    MA, with additional locations in Cambridge, MA, the company has    more than 120 employees.  <\/p>\n<p>    About Linden Capital Partners  <\/p>\n<\/p>\n<p>The rest is here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/stratadx-appoints-chief-financial-officer-110000056.html;_ylt=A2KLOzLQ_mxQLzAAf4n_wgt.\" title=\"StrataDx appoints Chief Financial Officer, Executive Vice President of Sales and Marketing, New Board Member\">StrataDx appoints Chief Financial Officer, Executive Vice President of Sales and Marketing, New Board Member<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> LEXINGTON, Mass., Oct.3, 2012 \/PRNewswire\/ --StrataDx, a leader in anatomic pathology services, announced today the appointments of Jim Agnello as Chief Financial Officer, Greg Richard as Executive Vice President of Sales &#038; Marketing, and Steve Casper to its Board of Directors.StrataDx provides clinicians with high-quality pathology services in the fields of dermatology, urology, podiatry, oral pathology, gastroenterology and gynecology. Jim Agnello, CPA, joins StrataDx as the Chief Financial Officer and brings over two decades of financial &#038; laboratory operational expertise. Mr <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/stratadx-appoints-chief-financial-officer-executive-vice-president-of-sales-and-marketing-new-board-member.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-246206","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246206"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=246206"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246206\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=246206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=246206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=246206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}